PMID: 7514451Jan 1, 1994Paper

The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
A FalangaT Barbui

Abstract

Activation of prothrombin and the subsequent reactions of thrombin with its substrates and its major inhibitors, antithrombin III (AT III) and heparin cofactor II (HC II), likely reflect both intravascular and extravascular coagulation. Several studies have reported increased in vivo coagulation in cancer. Whether the increased thrombin production in malignancy is accompanied by a corresponding increase in thrombin inhibition is unknown. This study quantified prothrombin fragment 1 + 2 (F1 + 2), thrombin-AT III (TAT), thrombin-AT III-vitronectin (TAT.V), and thrombin-HC II-vitronectin (THCII.V) in the plasmas of healthy volunteers (n = 37); patients with localized solid tumours before treatment was initiated (n = 39); and five patients with non-Hodgkin's lymphoma, both before and during weekly chemotherapy. Two of the five non-Hodgkin's lymphoma patients developed deep venous thrombosis (DVT) during chemotherapy. In normal plasma, where the concentrations of the four parameters likely reflect haemostasis, the sum of TAT, TAT.V and THCII.V was 61% that of F1 + 2, compared with 30% in cancer plasmas. In addition, the mean +/- SEM of F1 + 2 in the plasmas of cancer patients (1.56 +/- 0.09 nM) was significantly elevated (P < 0.001)...Continue Reading

Citations

May 25, 2001·International Journal of Hematology·A Falanga, M B Donati
Aug 26, 2003·Best Practice & Research. Clinical Haematology·Anna Falanga, Frederick R Rickles
Oct 31, 2002·Neoplasia : an International Journal for Oncology Research·Graham J CaineSean T Kehoe
Mar 16, 2011·Cardiology Research and Practice·Andrew D Blann, Simon Dunmore
Jul 27, 2002·The Lancet Oncology·G F NashA K Kakkar
Mar 23, 2002·The Lancet Oncology·Gregory Y H LipAndrew D Blann
Aug 13, 2014·Tuberculosis and Respiratory Diseases·Jeong Min LeeJeong-Seon Ryu
Nov 18, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Lisa F LinczJames W Denham
Feb 24, 2015·Annals of Hematology·Milla Elvi Linnea KuusistoOuti Kuittinen
Oct 29, 2000·Journal of Vascular Surgery·M H MeissnerD E Strandness
Sep 7, 2016·Journal of Thrombosis and Thrombolysis·Hisham BadreldinDanielle Carter
Nov 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil GoldenbergSusan Solymoss
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna Falanga, Marina Marchetti
Apr 1, 1996·Hematology/oncology Clinics of North America·K B Green, R L Silverstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.